title: [Alcohol withdrawal syndrome: clinical and analytical manifestations and treatment].
abstract: BACKGROUND
  The aim of this study was to analyze clinical manifestations and treatment aspects of alcohol withdrawal syndrome.
  
  
  METHODS
  A retrospective study of 212 clinical records.
  
  
  RESULTS
  The commonest withdrawal effects were tremulousness (68.7%) 7 agitation (67.3%) and hallucinations (46%). Most patients were male. The 64% recognize a period of relative or absolute abstinence less than two days, and a 67.8% have been previous incident of withdrawal syndrome. The commonest complications during hospital stay were rhabdomyolysis (26%). Time of symptoms were three days and mean of hospitalization were 14 days. The treatment used was the correction of fluid and electrolyte imbalance (93%) and B vitamins (98%). In relation to the use of drugs, in 84% of our patients we used benzodiazepines with longer-acting, and clomethiazole in 50% of cases. Mortality were 0.9%.
  
  
  CONCLUSIONS
  Patient with alcohol withdrawal syndrome was a male, previously drinker, with a period of abstinence less than two days. In addition to tremulousness and agitation, in our series, we wish to emphasize higher frequency of hallucinations, and the incidence of complications as rhabdomyolysis, despite of such response of treatment is good and mortality is low.
authors.affiliation: Departamento de Medicina Interna, Hospital General Universitario Gregorio Marañón, Madrid.
authors.forename: A
authors.initials: A
authors.lastname: Farfán Sedano
authors.forename: M
authors.initials: M
authors.lastname: Gómez Antúnez
authors.forename: M C
authors.initials: MC
authors.lastname: Martínez Cilleros
authors.forename: C
authors.initials: C
authors.lastname: Cuenca Carvajal
authors.forename: J M
authors.initials: JM
authors.lastname: Gironés Pérez
authors.forename: J
authors.initials: J
authors.lastname: García Castaño
mesh_terms: D000328:Adult; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D001569:Benzodiazepines; D002719:Chlormethiazole / Q000627:therapeutic use; D000431:Ethanol / Q000009:adverse effects*; D005260:Female; D018757:GABA Modulators / Q000627:therapeutic use; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D007902:Length of Stay; D008297:Male; D012189:Retrospective Studies; D012206:Rhabdomyolysis / Q000209:etiology; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis / Q000628:therapy; D013997:Time Factors; D014803:Vitamin B Complex / Q000627:therapeutic use
chemical_list: D014151:Anti-Anxiety Agents; D018757:GABA Modulators; D006993:Hypnotics and Sedatives; D002719:Chlormethiazole; D014803:Vitamin B Complex; D001569:Benzodiazepines; D000431:Ethanol
vernacular_title: Síndrome de abstinencia alcohólica: manifestaciones clínicas, analíticas y tratamiento.